. 2023 Apr 17;91:104566. doi: 10.1016/j.ebiom.2023.104566

Table 3.

Association of sCD14 with risk of CRC according to age at diagnosis and tumor location, HPFS 1993–2009.

	Quartile^a				Per SD increase^b	P_trend^c	P_{heterogeneity}
	1	2	3	4	Per SD increase^b	P_trend^c	P_{heterogeneity}
Age of CRC diagnosis							0.51
< median age [73.8 years]
No. of cases/controls	32/65	27/65	29/65	41/65
MV-adjusted OR (95% CI)^d	1 (referent)	1.08 (0.54–2.14)	1.31 (0.65–2.63)	2.03 (1.05–3.92)	1.42 (1.12–1.82)	0.03
≥ median age
No. of cases/controls	23/65	29/65	38/65	40/65
MV-adjusted OR (95% CI)^d	1 (referent)	1.61 (0.76–3.41)	1.49 (0.73–3.07)	1.51 (0.74–3.10)	1.10 (0.87–1.40)	0.38
Tumor location							0.79
Colon
No. of cases/controls	38/65	37/65	37/65	54/65
MV-adjusted OR (95% CI)^d	1 (referent)	1.23 (0.68–2.24)	1.13 (0.61–2.07)	1.81 (1.02–3.22)	1.25 (1.02–1.53)	0.05
Rectal
No. of cases/controls	11/65	17/65	17/65	19/65
MV-adjusted OR (95% CI)^d	1 (referent)	2.16 (0.88–5.27)	1.72 (0.70–4.24)	2.45 (1.01–5.92)	1.36 (1.02–1.82)	0.09

CI, confidence interval; CRC, colorectal cancer; HPFS, Health Professionals Follow-up Study (men only); MV, multivariable; OR, odds ratio; sCD14, soluble CD14; SD, standard deviation.

Quartile of sCD14 was defined based on the distribution in the controls.

SD for sCD14: 194 ng/ml.

P for trend was calculated using the median of each quartile as a continuous variable.

Adjusted for matching factors (age and time of blood draw [continuous]), as well as race (white, non-white), body mass index (continuous), family history of CRC (yes, no), prior history of sigmoidoscopy/colonoscopy (yes, no), regular use of aspirin (yes, no), regular use of non-steroidal anti-inflammatory drugs (yes, no), pack-years of smoking (continuous), physical activity (continuous), alcohol intake, red and processed meat, dietary fiber, total folate (from foods and supplements), calcium, and vitamin D intake (all continuous), and Alternative Healthy Eating Index-2010 score without alcohol (continuous).